Literature DB >> 33413331

Suppression of autophagy through JAK2/STAT3 contributes to the therapeutic action of rhynchophylline on asthma.

Hui Li1, Qianyu Bi2, Hongxia Cui3, Chuanfeng Lv4, Meng Wang5,6.   

Abstract

BACKGROUND: Asthma is a chronic inflammatory disease characterized by airway remodeling and inflammation. Rhynchophylline is a kind of indole alkaloid isolated from Uncaria rhynchophylla. Here we investigated the effect of rhynchophylline on autophagy in asthma.
METHODS: A mice model of asthma was established by ovalbumin challenge. Histopathological changes were assessed by hematoxylin-eosin staining, periodic acid-schiff staining and Masson staining. The levels of IgE in serum, interleukin-6 and interleukin-13 in bronchoalveolar lavage fluid, as well as the activities of superoxide dismutase and catalase in lung tissues were detected. The expression of autophagy-related genes and Janus kinase (JAK) 2/ signal transducer and activator of transcription (STAT) 3 signal was detected by western blot and immunofluorescence. Airway smooth muscle cells (ASMCs) were isolated, and the effect rhynchophylline on autophagy in ASMCs was explored.
RESULTS: Our data showed that rhynchophylline treatment alleviated inflammation, airway remodeling, and oxidative stress in asthma. In addition, autophagy, which was implicated in asthma, was suppressed by rhynchophylline with decreased level of autophagy-related proteins. Furthermore, rhynchophylline suppressed the JAK2/STAT3 signaling pathway, which was activated in asthma. In vitro study showed that rhynchophylline suppressed ASMC autophagy through suppressing the activation of JAK2/STAT3 signal.
CONCLUSIONS: Our study demonstrated that rhynchophylline can alleviate asthma through suppressing autophagy in asthma, and that JAK2/STAT3 signal was involved in this effect of rhynchophylline. This study indicates that rhynchophylline may become a promising drug for the treatment of asthma.

Entities:  

Keywords:  Asthma; Autophagy; JAK2; Rhynchophylline; STAT3

Year:  2021        PMID: 33413331      PMCID: PMC7792286          DOI: 10.1186/s12906-020-03187-w

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  21 in total

1.  Rhynchophyllin attenuates neuroinflammation in Tourette syndrome rats via JAK2/STAT3 and NF-κB pathways.

Authors:  Long Hongyan; Zhang Mengjiao; Wang Chunyan; Huang Yaruo
Journal:  Environ Toxicol       Date:  2019-06-23       Impact factor: 4.119

2.  Transcription Factor STAT3 Serves as a Negative Regulator Controlling IgE Class Switching in Mice.

Authors:  Paul Dascani; Chuanlin Ding; Xiangyu Kong; David Tieri; Xiaoling Hu; Huang-Ge Zhang; Daisuke Kitamura; Roberto Bolli; Eric C Rouchka; Jun Yan
Journal:  Immunohorizons       Date:  2018-12-05

3.  Rhynchophylline Attenuates Tourette Syndrome via BDNF/NF-κB Pathway In Vivo and In Vitro.

Authors:  Hongyan Long; Jie Ruan; Mengjiao Zhang; Chunyan Wang; Yaruo Huang
Journal:  Neurotox Res       Date:  2019-06-26       Impact factor: 3.911

4.  Rhynchophylline attenuates LPS-induced pro-inflammatory responses through down-regulation of MAPK/NF-κB signaling pathways in primary microglia.

Authors:  Yu Song; Rong Qu; Shenghua Zhu; Ruiguo Zhang; Shiping Ma
Journal:  Phytother Res       Date:  2012-02-10       Impact factor: 5.878

5.  The role of rhynchophylline in alleviating early brain injury following subarachnoid hemorrhage in rats.

Authors:  Yan Zhang; Juan Sun; Shijie Zhu; Ting Xu; Jianfei Lu; Hongbin Han; Changman Zhou; Junhao Yan
Journal:  Brain Res       Date:  2015-11-26       Impact factor: 3.252

6.  STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model.

Authors:  A C Gavino; K Nahmod; U Bharadwaj; G Makedonas; D J Tweardy
Journal:  Allergy       Date:  2016-06-23       Impact factor: 13.146

7.  STAT3 regulates cytokine expression in peripheral blood mononuclear cells from asthma patients.

Authors:  Q Yang; W Xu; Y Long; J Kuang; J Li
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2017-09-30       Impact factor: 1.770

8.  IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease.

Authors:  Ourania Koltsida; Michael Hausding; Athanasios Stavropoulos; Sonja Koch; George Tzelepis; Caroline Ubel; Sergei V Kotenko; Paschalis Sideras; Hans A Lehr; Marcus Tepe; Kevin M Klucher; Sean E Doyle; Markus F Neurath; Susetta Finotto; Evangelos Andreakos
Journal:  EMBO Mol Med       Date:  2011-05-03       Impact factor: 12.137

Review 9.  Severe Asthma and Biological Therapy: When, Which, and for Whom.

Authors:  Paola Rogliani; Luigino Calzetta; Maria Gabriella Matera; Rossella Laitano; Beatrice Ludovica Ritondo; Nicola A Hanania; Mario Cazzola
Journal:  Pulm Ther       Date:  2019-12-26

10.  Rhynchophylline Attenuates Senescence of Endothelial Progenitor Cells by Enhancing Autophagy.

Authors:  Lin Lin; Lei Zhang; Xin-Tong Li; Jing-Kang Ji; Xiao-Qing Chen; Yun-Lun Li; Chao Li
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

View more
  3 in total

Review 1.  Autophagy in Rheumatic Diseases: Role in the Pathogenesis and Therapeutic Approaches.

Authors:  Alessandra Ida Celia; Serena Colafrancesco; Cristiana Barbati; Cristiano Alessandri; Fabrizio Conti
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

2.  Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway.

Authors:  Chuanfeng Lv; Hui Li; Hongxia Cui; Qianyu Bi; Meng Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Conciliatory Anti-Allergic Decoction Attenuates Pyroptosis in RSV-Infected Asthmatic Mice and Lipopolysaccharide (LPS)-Induced 16HBE Cells by Inhibiting TLR3/NLRP3/NF-κB/IRF3 Signaling Pathway.

Authors:  Ya-Qin Chen; Yan Zhou; Qi-Li Wang; Jian Chen; Hua Chen; Hui-Hui Xie; Lan Li
Journal:  J Immunol Res       Date:  2022-09-29       Impact factor: 4.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.